MSD Korea launches Brenzys™ in Korea for the first time
On the 3rd, MSD Korea(CEO Dong-wook Hyun) announced Samsung Bioepis will launch Brenzys™, a biosimilar the company developed and commercializes, for the first time in the world.
Like etanercept, the original, Brenzys™ can be used as a treatment for rheumatoid arthritis, psoriatic arthritis, spon...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
